Sign up
Pharma Capital

It's 'all systems go' as ReNeuron gears up for Phase III stroke disability study

Michael Hunt, CFO at ReNeuron PLC (LON:RENE) sat down with Proactive's Andrew Scott on the day of their results for the year to the end of March 2017 to bring us up to speed on the latest with their therapeutic development programmes.

 

View full RENE profile

ReNeuron Group Plc Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.